Zacks Investment Research upgraded shares of FIBROCELL SCIEN (FCSC) from NEUTRAL to OUTPERFORM on September 23, 2014, with a target price of $3.50.
Fibrocell Science, Inc. is a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications. The Company's clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burns with a patient's own, or autologous, fibroblast cells produced in the Company's proprietary Fibrocell Process. Fibrocell Science, through its subsidiary, Agera Laboratories, Inc., also develops and markets a skin care product line primarily in the United States and Europe. The Company is headquartered in Exton, Pennsylvania.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on FIBROCELL SCIEN (FCSC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment